PharmaSeq

Home Company News & Events Press Releases 2010 PharmaSeq Receives Government Grant to Develop Nanotechnology-based Protein Multiplex Assay for Prostate Cancer

Press Releases

PharmaSeq Receives Government Grant to Develop Nanotechnology-based Protein Multiplex Assay for Prostate Cancer

Monmouth Junction, NJ, August 20, 2010. PharmaSeq, Inc., is pleased to announce the award of a $1.2 million two-year SBIR Phase II grant for a project entitled "Use of Silver Nanostructures on Microtransponders in Ultra-Sensitive Assay". The grant was awarded by the National Cancer Institute of the NIH. Its purpose is to support the development of a next-generation test for prostate cancer detection based on breakthrough nanotechnology principles. The diagnostic will consist of a microtransponder-based, multiplex antibody assay and a bench-top analyzer. In addition to PharmaSeq, work will be performed at the Fisher Biorepository and Biomarker Laboratory in the Brady Urological Research Institute at Johns Hopkins Hospital in Baltimore and the Center for Commercialization of Fluorescent Technologies at the University of North Texas Health Science Center in Fort Worth, TX.

The benefits of the program include the commercial development of a non-invasive urine test for the early detection of prostate cancer using several biomarkers associated with the disease, combined with a highly innovative application of fluorescence enhanced techniques on the PharmaSeq microtransponder. The instrumentation and the assay platform will also be made available for a wide variety of additional genetic and proteomic-type tests.

Dr. Wlodek Mandecki, President of PharmaSeq, Inc., said: "This grant award validates the scientific community's recognition of the potential for our microtransponder technology as a powerful tool for multiplex protein diagnostics. The grant will allow us to develop an improved assay for early detection of prostate cancer that will undoubtedly reduce the variable performance with the current method, thereby leading to fewer unnecessary procedures".

The assay detects several proteins using biomarker-specific antibodies immobilized on microtransponders. Each microtransponder is composed of photocells, an antenna and memory that correlates the serial number with the identity of the antibody probe attached to its surface. In an assay, a patient sample is combined with a set of microtransponders, each with a unique serial number corresponding to a different probe, and visualized with a fluorescent reagent. Sensitivity is enhanced up to fifty-fold using microtransponders that have been configured with silver nanostructures. The enhanced signal intensity on the microtransponder surface is quantified in a flow-based analyzer that also determines the serial number of the microtransponder. Microtransponders and readers are all designed and built by PharmaSeq.

A research article describing the Phase I work and reporting a dramatic increase in assay sensitivity when silver nanostructures are placed on microtransponders has been published in Analytical and Bioanalytical Chemistry, a well-known scientific journal.

For further information, please contact Dr. Richard Morris, CEO, or Dr. Wlodek Mandecki, President, at (732) 355-0100 ext 11.

PharmaSeq, Inc.
11 Deer Park Drive, Suite 104
Monmouth Junction, NJ 08852
Find us on the web at: www.pharmaseq.com.

Home Company News & Events Press Releases 2010 PharmaSeq Receives Government Grant to Develop Nanotechnology-based Protein Multiplex Assay for Prostate Cancer